GeneralConnection.com ➔ Dictionary
Dictionary Search

factor ix

Synonyms

Noun

1. Christmas factor

2. factor IX, coagulation factor, clotting factor

Usage
Prophylaxis vs. On-Demand Treatment for Hemophilia B - HealthCentral
Factor IX-Padua AAV gene therapy in hemophilia B: phases 1/2 and 3 trials - Nature
Single-Dose Gene Therapy Shows Promising Safety, Efficacy, and Patient-Reported Outcomes in Hemophilia B - Docwire News
Hemophilia B Treatment: Options and Advances - HealthCentral
Single-infusion etranacogene dezaparvovec in men with hemophilia B (factor IX activity ≤2 IU/dL) was associated with sustained factor IX expression and reduced annualized bleeding rates through 5 years - Vera Health
Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B - The New England Journal of Medicine
Marstacimab sBLA for Expanded Use in Hemophilia A or B Gets Priority Review - Hematology Advisor
Angela Dugalic is UCLA’s X-factor - The IX Sports
Hemophilia B drug Idelvion is now available at KHF-run clinics - koreabiomed.com
FDA Expands Marstacimab Indication in Hemophilia A and B - Conexiant
Explainer 2025 Why Is Hemophilia B Called Christmas Disease - Global Biotechnology Company
Pfizer receives EC approval for Hympavzi to treat haemophilia - Pharmaceutical Technology
Tailored collagen binding of albumin-fused hyperactive coagulation factor IX dictates in vivo distribution and functional properties - Nature
Advances in hemophilia, sickle cell disease, and thalassemia - Penn Medicine
EAHAD 2026: Nine-Year Outcomes of Gene Therapy - European Medical Journal
Hemophilia B Gene Therapy Continues to Reduce Bleeding - Medscape
How durable is gene therapy for haemophilia B? - Nature
ASH: CSL proves efficacy of hemophilia B gene therapy Hemgenix holds up after 5 years - Fierce Pharma
Optimization of hemophilia B treatment via population PK modeling of rIX-FP, including a 3-week regimen - Frontiers
Gene Therapy Maintains Efficacy in Hemophilia B Out to 5 Years - MedPage Today
Gene Therapy Supply Runs Out, Company Warns of Treatment Delays - MedPage Today
Clinical Scenarios in Hospitalized Patients With Hemophilia - Cureus
Eloctate, Alprolix control bleeds in hemophilia patients’ major surgeries - Hemophilia News Today
How Gene Therapy Is Transforming Hemophilia B Treatment - Docwire News
Sanofi’s hemophilia B therapy Alprolix approved for 6-month room-temperature storage - koreabiomed.com
Biogen Idec to Present Data from Hematology Programs, Including ELOCTATE™ and ALPROLIX® at ASH Annual Meeting - Biogen
Hemophilia Patients in Afghanistan Report Shortages of Clotting Factors - TOLOnews
Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant - The New England Journal of Medicine
AAV gene therapy shows durable benefit in hemophilia B - 2 Minute Medicine
Coagulation factor IX analysis in bioreactor cell culture supernatant predicts quality of the purified product - Nature
First subject dosed in Be Biopharma’s trial of haemophilia B therapy - Clinical Trials Arena
Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B - The New England Journal of Medicine
U.S. Food and Drug Administration approves CSL’s HEMGENIX® (etranacogene dezaparvovec-drlb), the first gene therapy for hemophilia B - BioMelbourne Network
The National “New Methods” Decision Forum in Norway recommends CSL’s gene therapy HEMGENIX® for adults with severe or moderately severe haemophilia B without a history of Factor IX inhibitors - Mynewsdesk
Successful management with regular factor IX replacement during pregnancy in a hemophilia B carrier: A case report - Wiley & Sons
Effects of codon optimization on coagulation factor IX translation and structure: Implications for protein and gene therapies - Nature
A novel snake venom C-type lectin-like protein modulates blood coagulation by targeting von Willebrand factor and coagulation factor IX - Nature
Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B - The New England Journal of Medicine
Systemic delivery of factor IX messenger RNA for protein replacement therapy - PNAS
Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B - The New England Journal of Medicine
Genome wide CRISPR/Cas9 screen identifies the coagulation factor IX (F9) as a regulator of senescence - Nature
Hemophilia B Gene Therapy Demonstrates Long-Term Efficacy and Safety - Hematology Advisor
HTC Population Profile Patient Characteristics - Centers for Disease Control and Prevention | CDC (.gov)
X-Linked Thrombophilia with a Mutant Factor IX (Factor IX Padua) - The New England Journal of Medicine
Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec) Over Five Years - Mynewsdesk
Plasma Kallikrein Contributes to Coagulation in the Absence of Factor XI by Activating Factor IX - American Heart Association Journals
FIX It in One Go: Enhanced Factor IX Gene Therapy for Hemophilia B - ScienceDirect.com
Kallikrein directly interacts with and activates Factor IX, resulting in thrombin generation and fibrin formation independent of Factor XI - PNAS
PBPK modeling of recombinant factor IX Fc fusion protein (rFIXFc) and rFIX to characterize the binding to type 4 collagen in the extravascular space - Wiley
First gene therapy to treat haemophilia B - European Medicines Agency (EMA)
Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies - Wiley Online Library
This gene therapy costs $5 million a dose. Is it worth the price? - SMH.com.au
Use of anti-haemophilia medicine suspended across Punjab after reports of adverse reactions - The Tribune
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial - Applied Clinical Trials Online
SRY-Box transcription factor 9 triggers YAP nuclear entry via direct interaction in tumors - Nature
A coagulation factor moonlights in the heart - Science | AAAS
UC San Diego Health First to Offer Novel Gene Therapy for Hemophilia B - UC San Diego Health
Speaking with the man, first in Canada, to receive breakthrough hemophilia B gene therapy - CTV News
FDA Accepts Biogen Idec’s Biologics License Application for First Long-Lasting Factor IX Therapy for Hemophilia B - Biogen
Glucocorticoids increase adiposity by stimulating Krüppel-like factor 9 expression in macrophages - Nature
Hemophilia B Gene Therapy Produces Durable Response for 90% of Participants - AJMC
Factor Levels Lower Than 50% Associated With Postpartum Complications in Patients With Hemophilia - Hematology Advisor
Intellia opts out of hemophilia B gene editing work with Regeneron - Fierce Biotech
Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A - The New England Journal of Medicine
Anticoagulant Protein S Targets the Factor IXa Heparin-Binding Exosite to Prevent Thrombosis - American Heart Association Journals
Association Between Hepatic Triglyceride Content and Coagulation Factors: - American Heart Association Journals
Gene therapy fails to induce sustained factor IX activity for patients with hemophilia B - Healio
Regeneron and Intellia Therapeutics Expand Collaboration to Develop CRISPR/Cas9-Based Treatments - Intellia Therapeutics
Evaluation of a New Concentrate for the Treatment of Factor IX Deficiency - The New England Journal of Medicine
Novel Insights and New Developments Regarding Coagulation Revealed by Studies of the Anti-Factor IXa (Activated Factor IX)/Factor X Bispecific Antibody, Emicizumab - American Heart Association Journals
Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response - Nature
Loss of Krüppel-like factor 9 deregulates both physiological gene expression and development - Nature
Coagulation factors VII, IX and X are effective antibacterial proteins against drug-resistant Gram-negative bacteria - Nature
Etranacogene dezaparvovec gene therapy reduces bleeding in severe hemophilia B - 2 Minute Medicine
Sustained correction of bleeding disorder in hemophilia B mice by gene therapy - PNAS
Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector - Nature
Phase 1–2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B - The New England Journal of Medicine
Crystal structure of an anticoagulant protein in complex with the Gla domain of factor X - PNAS
Single-dose gene therapy is potentially life-changing for adults with hemophilia B - Penn Medicine
Pfizer: Beqvez Gene Therapy Decreases Bleeding Rates in Hemophilia B Patients - 2 Minute Medicine
Sustained Clinical Benefit of AAV Gene Therapy in Severe Hemophilia B - The New England Journal of Medicine
Effective Blood Clotting Treatment:Pharmacogenomic Studies of ADAMTS13 - fda.gov
Case Report: Severe hemophilia B patient with inhibitor and anaphylaxis reaction to FIX, successfully managed with concizumab prophylaxis therapy - Frontiers
Personal Story: Carrie - Centers for Disease Control and Prevention | CDC (.gov)
Fidanacogene Elaparvovec Shows Strong Results in Open-Label Phase 3 Study - AJMC
Hemophilia B gene therapy demonstrates long-term success - St. Jude Children's Research Hospital
EMA Authorizes Hemophilia B Gene Therapy - Medscape
Low-dose AAVS3 gene therapy is efficacious for treating patients with hemophilia B - 2 Minute Medicine
A genetic analysis of 23 Chinese patients with hemophilia B - Nature
Pulmonary Hemorrhage: An Unusual Life-Threatening Presentation of Factor IX Deficiency in a Monochorionic-Diamniotic Twin Neonate - Cureus
New Biogen Hemophilia Data At ISTH Congress to Highlight Extension Study Outcomes and Pediatric Use - Biogen
Hemophilia B Gene Therapy Shows Promise in Clinical Trial - Genetic Engineering and Biotechnology News
FDA Approves Fidanacogene Elaparvovec-dzkt as One-Time Gene Therapy for Adults With Hemophilia B - Pharmacy Times
A Machine Learning Framework Predicts the Clinical Severity of Hemophilia B Caused by Point-Mutations - Frontiers
Factor IX product launched in US - MDEdge
Hemophilia Gene Therapies Show Effectiveness and Safety in NEJM Reports - Inside Precision Medicine
The Prevalence of Proteolytic Antibodies against Factor VIII in Hemophilia A - The New England Journal of Medicine
Is Hemophilia a Nosologic Entity? - ScienceDirect.com
World Haemophilia Day on April 17 - Manorama Yearbook
FDA Approves Second Gene Therapy for Hemophilia B - Medscape
Foreign Language Equivalents
Foreign Language Equivalents of 'factor ix'
Language Equivalent   Language Equivalent
French    Spanish
Misspellings - Typos
facttor ix,   faactor ix,   factor ic,   factoe ix,   factor iix,   factor x,   faxtor ix,   fatcor ix,   factot ix,   factor xi,   factorr ix,   ffactor ix,   facotr ix,   factro ix,   factpr ix,   dactor ix,   fctor ix,   facror ix,   afctor ix,   fsctor ix,   factor i,   facto ix,   gactor ix,   factorix,   facctor ix,   factor ux,   factor ox,   factir ix,   factr ix,   fator ix,   factoor ix,   factor ix,   facto rix,   fcator ix,   favtor ix,   factor ixx,   facyor ix,   actor ix,   facter ix,   factor iz,   facor ix,   factori x
Words Starting with Letter - 'A'
a a battery a billion
a bit a bit much a capella singing
a cappella singing a couple of a few
a fortiori a good deal a great deal
a horizon a hundred a hundred and one
a hundred thousand a hundred times a kempis
a la carte a la mode a level
a little a lot a million
Go to Page 1              Go to Page 2 »   
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z